Trevarx Biomedical
Develops new radiopharmaceuticals to diagnose and guide the treatment of cancer, brain disorders, and other human diseases
Unify Pharmaceuticals
Develops therapeutics for treating neurodegenerative diseases and other neurological diseases
Unleash Immuno Oncolytics
Develops genetically-engineered adenoviruses to harness the immune system to fight cancer
Viosera Therapeutics
Discovers synergies between approved drugs and develop combinations of drugs that suppress resistance
Biotech startup, which has raised more than $200M in VC funding, launches clinical trial for cancer drug
St. Louis-based clinical-stage biotechnology startup Wugen, which has raised more than $200 million in venture funding, has launched a clinical trial for one of its cancer-fighting therapies.
Wugen announces first patient dosed in phase 1/2 trial of WU-CART-007
Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that the first patient has been dosed in a Phase 1/2 trial of WU-CART-007 for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).
Valo Health announces acquisition of Courier Therapeutics
A biotechnology company founded in 2015 by Dr. Alexander Krupnick and colleagues at Washington University in St. Louis and Mercury Fund, Courier developed a protein therapeutics platform that has the potential to make cancer immunotherapy safer and more efficacious than treatments currently available or in development.
Arch Oncology secures $105 million Series C financing
“Arch Oncology’s highly differentiated approach to the development of anti-CD47 agents is a promising development in the immuno-oncology space,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology.